Mineralys Therapeutics
Radnor, PA
Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.
mineralystx.comCompany Details
Founded
- 2020
Employees
- 51 employees
Raised
- $453,000,000
Headquarters Location
- Radnor, PA
Public
- Yes
Acquired
- No
CEO
Jon Congleton
Founders
- BT Slingsby
Company Collections
These are collections Mineralys Therapeutics is a part of. Click on the collection name to view similar companies.
Mineralys Therapeutics' Industries
Current Job Listings
Mineralys Therapeutics Headquarters Location
Total Amount Raised: $453,000,000
Mineralys Therapeutics Funding Rounds
Post Ipo Equity
$175,000,000
Post Ipo Equity
$120,000,000
Post Ipo Equity Investors
TCGXRA Capital ManagementSamsara BioCapitalOrbiMed AdvisorsVenrock Healthcare Capital PartnersIPO
Unknown
Series B
$118,000,000
Series B Investors
Andera PartnersRA Capital ManagementSectoral Asset ManagementRock Springs CapitalRTW InvestmentsYsios CapitalAdams Street PartnersHealthCor Partners ManagementSamsara BioCapitalSr OneHBM Healthcare InvestmentsCatalys PacificBoulder VenturesSeries A
$40,000,000
Series A Investors
HBM Healthcare InvestmentsSamsara BioCapitalCatalys PacificAdams Street Partners
Mineralys Therapeutics Reviews
0 out of 5 stars
Based on 0 reviews
Review data
Share your thoughts
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Mineralys Therapeutics.